Sandoz in oncology biosimilar deal with China’s Bio-Thera

Drugs

The biosimilar is a recombinant humanized monoclonal IgG1 antibody that targets vascular endothelial growth factor (VEGF), a key mediator of angiogenesis in cancer, and is used in combination with other treatments, said the partners.

Guangzhou, China based Bio-Thera will maintain responsibility for development and manufacturing, Sandoz will have the right to commercialize the medicine upon approval in the US, Europe, Canada and selected other countries.

According to the terms of the agreement, the Chinese company will receive an upfront and milestone payments and is entitled to receive profit share payments in the partnered territory.

A spokesperson for Sandoz, a division of pharma giant, Novartis, told us about the rationale behind its interest in BAT1706: ”Besides being an important offering in its own right, a major reason is that this product, once launched, would complement and build on our leading off-patent oncology portfolio.”

That portfolio comprises four marketed oncology biosimilars and over 50 generic medicines worldwide.

Sandoz said its sees external collaborations as complementary to its internal programs, with “an appropriate strategic balance enabling us to drive patient access by delivering portfolio breadth, balancing risks and costs and positioning us to play a leading role in the future biosimilar market.”

Deal spree

Bio-Thera has been busy of late.

In August, the Chinese firm and UK listed, Hikma Pharmaceuticals, inked a pact to commercialize ustekinumab biosimilar product, BAT2206, which is indicated for the treatment of autoimmune diseases such as active psoriatic arthritis.

Products You May Like

Leave a Reply

Your email address will not be published. Required fields are marked *